WO2009085198A3 - Combination of metformin r-(+)-lipoate and antiobesity agents for the treatment of diabetic hyperglycemia and diabetic complications - Google Patents

Combination of metformin r-(+)-lipoate and antiobesity agents for the treatment of diabetic hyperglycemia and diabetic complications Download PDF

Info

Publication number
WO2009085198A3
WO2009085198A3 PCT/US2008/013878 US2008013878W WO2009085198A3 WO 2009085198 A3 WO2009085198 A3 WO 2009085198A3 US 2008013878 W US2008013878 W US 2008013878W WO 2009085198 A3 WO2009085198 A3 WO 2009085198A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic
treatment
lipoate
metformin
combination
Prior art date
Application number
PCT/US2008/013878
Other languages
French (fr)
Other versions
WO2009085198A2 (en
Inventor
Banavara L. Mylari
Original Assignee
Indigene Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indigene Pharmaceuticals, Inc. filed Critical Indigene Pharmaceuticals, Inc.
Publication of WO2009085198A2 publication Critical patent/WO2009085198A2/en
Publication of WO2009085198A3 publication Critical patent/WO2009085198A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed are pharmaceutical compositions, methods of treatment, and kits for the treatment of Type 2 diabetic hyperglycemia and diabetic complications using combination treatments comprising metformin R-(+)-lipoate and antiobesity agents.
PCT/US2008/013878 2007-12-20 2008-12-19 Combination of metformin r-(+)-lipoate and antiobesity agents for the treatment of diabetic hyperglycemia and diabetic complications WO2009085198A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US892207P 2007-12-20 2007-12-20
US61/008,922 2007-12-20

Publications (2)

Publication Number Publication Date
WO2009085198A2 WO2009085198A2 (en) 2009-07-09
WO2009085198A3 true WO2009085198A3 (en) 2009-09-03

Family

ID=40473932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/013878 WO2009085198A2 (en) 2007-12-20 2008-12-19 Combination of metformin r-(+)-lipoate and antiobesity agents for the treatment of diabetic hyperglycemia and diabetic complications

Country Status (1)

Country Link
WO (1) WO2009085198A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112007156A (en) * 2019-05-30 2020-12-01 复旦大学 Application of cannabinoid receptor drug in preparation of drug for treating myocardial cell necrotic apoptosis
CN112755189A (en) * 2019-11-02 2021-05-07 复旦大学 Use of type 1 cannabinoid receptor antagonists for the preparation of a medicament for the treatment of myocardial cell apoptosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220301A1 (en) * 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
WO2007131219A2 (en) * 2006-05-05 2007-11-15 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220301A1 (en) * 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
WO2007131219A2 (en) * 2006-05-05 2007-11-15 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRAY ET AL: "Drug Treatment of the Overweight Patient", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 132, no. 6, 10 May 2007 (2007-05-10), pages 2239 - 2252, XP022072510, ISSN: 0016-5085 *

Also Published As

Publication number Publication date
WO2009085198A2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2009129246A3 (en) Compositions and methods for preparing and using same
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2008060374A3 (en) Methods and compositions useful for diabetic wound healing
EP1859793A4 (en) Novel combinational use of sulfonamide compound
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2008054676A3 (en) Medical devices and methods of using the same
WO2005079143A3 (en) Topical formulations for the treatment of skin conditions
WO2007044026A3 (en) Compositions comprising modified collagen and uses therefore
WO2007011962A3 (en) Treatment of cancer
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
MX2009007254A (en) Tablet-in-tablet compositions.
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2009011889A3 (en) Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2008013893A3 (en) Diagnosis and treatment of age related macular degeneration
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007133944A3 (en) Topical administration of acyclovir
WO2007144057A3 (en) Antimicrobial carbon
WO2008062467A3 (en) Cultured melanocytes on biopolymers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08866735

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08866735

Country of ref document: EP

Kind code of ref document: A2